Hence, our preliminary results suggest that some adult patients with r/r Burkitt lymphoma can benefit from novel treatment strategies involving CD19/CD22 CAR T cell immunotherapy or its combination with ASCT. Here, CD19 is linked to Burkitt lymphoma.